Developing nations like India should consider consenting to pharma’s indemnity demand, albeit with sharp drafting of the nuances and secure supplies of COVID-19 vaccines, given that a large part of the population is yet to get inoculated, an assessment by legal and other experts suggests.
These are, after all, extraordinary times and "indemnity hesitancy" may come at the cost of losing out on procuring the...